Antibody response to influenza vaccination in the elderly: A quantitative review

Katherine Goodwin, Cecile Viboud, Lone Simonsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

We performed a quantitative review of 31 vaccine antibody response studies conducted from 1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly versus younger adults. We did a weighted analysis of the probability of vaccine response (measured as seroconversion and seroprotection) for each vaccine component (H1, H3 and B antigens). Using a multiple regression model, we adjusted for factors that might affect the vaccine response. The adjusted odds-ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 in terms of seroconversion and seroprotection to all three antigens. The CDC estimates of 70–90% clinical vaccine efficacy in young adults and these estimates suggest a corresponding clinical efficacy in the elderly of 17–53% depending on circulating viruses. We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly.
OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind24
Udgave nummer8
Antal sider11
ISSN0264-410X
DOI
StatusUdgivet - 2006
Udgivet eksterntJa

Citer dette

@article{15c509f4990843e991be15bd033d06ec,
title = "Antibody response to influenza vaccination in the elderly: A quantitative review",
abstract = "We performed a quantitative review of 31 vaccine antibody response studies conducted from 1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly versus younger adults. We did a weighted analysis of the probability of vaccine response (measured as seroconversion and seroprotection) for each vaccine component (H1, H3 and B antigens). Using a multiple regression model, we adjusted for factors that might affect the vaccine response. The adjusted odds-ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 in terms of seroconversion and seroprotection to all three antigens. The CDC estimates of 70–90{\%} clinical vaccine efficacy in young adults and these estimates suggest a corresponding clinical efficacy in the elderly of 17–53{\%} depending on circulating viruses. We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly.",
author = "Katherine Goodwin and Cecile Viboud and Lone Simonsen",
year = "2006",
doi = "10.1016/j.vaccine.2005.08.105",
language = "English",
volume = "24",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier Ltd",
number = "8",

}

Antibody response to influenza vaccination in the elderly: A quantitative review. / Goodwin, Katherine; Viboud, Cecile; Simonsen, Lone.

I: Vaccine, Bind 24, Nr. 8, 2006.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Antibody response to influenza vaccination in the elderly: A quantitative review

AU - Goodwin, Katherine

AU - Viboud, Cecile

AU - Simonsen, Lone

PY - 2006

Y1 - 2006

N2 - We performed a quantitative review of 31 vaccine antibody response studies conducted from 1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly versus younger adults. We did a weighted analysis of the probability of vaccine response (measured as seroconversion and seroprotection) for each vaccine component (H1, H3 and B antigens). Using a multiple regression model, we adjusted for factors that might affect the vaccine response. The adjusted odds-ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 in terms of seroconversion and seroprotection to all three antigens. The CDC estimates of 70–90% clinical vaccine efficacy in young adults and these estimates suggest a corresponding clinical efficacy in the elderly of 17–53% depending on circulating viruses. We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly.

AB - We performed a quantitative review of 31 vaccine antibody response studies conducted from 1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly versus younger adults. We did a weighted analysis of the probability of vaccine response (measured as seroconversion and seroprotection) for each vaccine component (H1, H3 and B antigens). Using a multiple regression model, we adjusted for factors that might affect the vaccine response. The adjusted odds-ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 in terms of seroconversion and seroprotection to all three antigens. The CDC estimates of 70–90% clinical vaccine efficacy in young adults and these estimates suggest a corresponding clinical efficacy in the elderly of 17–53% depending on circulating viruses. We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly.

U2 - 10.1016/j.vaccine.2005.08.105

DO - 10.1016/j.vaccine.2005.08.105

M3 - Journal article

VL - 24

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 8

ER -